Effects of fluoxetine and ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients

Gerra, Gilberto; Caccavari, R.; Delsignore, R; Bocchi, R.; Fertonani, Giuseppe; Passeri, M

doi:10.1016/s0011-393x(05)80480-1

Cited by 61 publications

(20 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, Naranjo et al (1994) found that, although fluoxetine 60 mg/day reduced the desire for alcohol, both in an experimental bar setting and when compared with PLA in an outpatient trial, it did not significantly reduce alcohol consumption. Using a crossover design, Gerra et al (1992) compared the effects of fluoxetine 40 mg/day, acamprosate, and PLA for treatment of alcoholism. These investigators found that although both active medications were superior to PLA in reducing the number of drinks consumed, the effect of fluoxetine was significant only among patients with a parental history of alcoholism.…”

mentioning

confidence: 99%

Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial

Kranzler

Modesto‐Lowe

Kirk

2000

Neuropsychopharmacology

208

122

View full text Add to dashboard Cite

mentioning

confidence: 99%

Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial

Kranzler

Modesto‐Lowe

Kirk

2000

Neuropsychopharmacology

208

122

View full text Add to dashboard Cite

“…All papers indicated the necessity for a better characterization of the patients, separating patients, who could benefit from acamprosate and who would not. In 1992, a paper reported that acamprosate only reduces the number of drinks in alcohol-dependent patients with no family history of alcoholism [9]. It has been reported recently that only the motivated patients profit from taking acamprosate [29].…”

Section: Resultsmentioning

confidence: 99%

The European Acamprosate Trials: Conclusions for Research and Therapy

Lesch

Riegler

Gutiérrez

et al. 2001

Journal of Biomedical Science

View full text Add to dashboard Cite

In an excellent methodological approach, the European acamprosate study project showed that acamprosate increases sobriety times. In one randomized prospective study (n = 260) comparing acamprosate and placebo, with a 1-year treatment phase and 1-year follow-up phase, the authors found that acamprosate is effective only in Lesch type I and type II patients. To investigate the possible influence of diagnostic subgrouping, we applied the Lesch typology in a co-work with the main researchers of the UK study. The UK results concerning acamprosate’s effects in the types do not mirror the Vienna results, but the numbers of type I and type II patients, retrospectively found as included in the UK centers, were too small for any conclusions. The distribution of the types points to the fact that too many type III and IV patients had been included to give acamprosate the chance to be effective. Following our typology and also these studies, we developed special treatment approaches. For relapse prevention studies, the cumulative abstinence duration together with the Lesch typology seems to be promising.

show abstract

“…Subsequently, inpatient alcoholics pretreated with fl uoxetine 80 mg/day and given access to alcohol reduced their intake only during the fi rst week of treatment (Gorelick and Paredes, 1992). Gerra et al (1992) compared the effects of fl uoxetine 40 mg/day, acamprosate, and placebo in family history-positive (FHP) and family history-negative (FHN) alcoholics using a crossover design. Both active medications were superior to placebo in reducing the number of drinks consumed, but only FHP patients responded to fl uoxetine and only FHN patients responded to acamprosate.…”

Section: Medications That Directly Reduce Alcohol Consumptionmentioning

confidence: 99%

Pharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress

Zindel¹,

Kranzler²

2014

J. Stud. Alcohol Drugs Suppl.

View full text Add to dashboard Cite

ABSTRACT. Modern pharmacotherapy for alcohol dependence has its roots in the failure of National Prohibition in the United States and the rise of the disease model of alcoholism (embodied in Alcoholics Anonymous). In 1948, disulfi ram was the fi rst medication approved by the U.S. Food and Drug Administration (FDA) to treat alcohol dependence, but its effi cacy has not been supported by randomized controlled trials. In the 1960s, benzodiazepines replaced older treatments for alcohol withdrawal, but sedative and dependence-producing effects limit their utility in the postwithdrawal period. In the 1980s, the focus shifted to the treatment of co-occurring psychiatric disorders and medications that modify negative mood states, which contribute to relapse to heavy drinking. In the 1990s, developments in neurobiology implicated specifi c neurotransmitter systems underlying alcohol's effects, culminating in the 1994 approval by the FDA of the opioid antagonist naltrexone to treat alcohol dependence. In 2006, the FDA approved a long-acting formulation of naltrexone. Recently, nalmefene, another opioid receptor antagonist, was approved in Europe for as-needed use to reduce heavy drinking. Acamprosate, an amino acid derivative, fi rst approved in France in 1989, received FDA approval in 2004. However, the benefi cial effects of the approved medications are only modestly greater than those of placebo, and their use is limited. Topiramate, currently under investigation for alcohol dependence, has greater effi cacy but a variety of adverse effects. In addition to the identifi cation of novel compounds, the future of alcohol dependence pharmacotherapy will depend on developments in pharmacogenetics, in which genetic variation that moderates treatment effi cacy and adverse effects is used to personalize treatment. (J. Stud.

show abstract

Effects of fluoxetine and ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients

Cited by 61 publications

References 9 publications

Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial

Naltrexone vs. Nefazodone for Treatment of Alcohol Dependence A Placebo-Controlled Trial

The European Acamprosate Trials: Conclusions for Research and Therapy

Pharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress

Contact Info

Product

Resources

About